Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: Oblivious who wrote (804)	4/28/1998 9:32:00 PM
From: Oblivious	Read Replies (1) \| Respond to of 1202

I found this on Yahoo. I don't know how factual it is. Dave ---------------------------------------------------------------------- cococorky (50/M) Apr 28 1998 9:25PM EDT I listened to the conference call and Mr. Dow was much more positive than the discussion this morning on CNBC. Some of the issues that were discussed were that countries such as Korea and Taiwan look to the FDA as a basis for approval in their countries. Japan has a parallel track of approval as the FDA He indicated they are close to completing the MHW?? study. He indicated that in Japan coronary heart disease is not as significant as in the U.S. He estimated the potential to be 25-30% of that of the U.S. But he indicated this may increase as they develop more of our lifestyle. At this time he felt the market for what was approved by the panel to be about 60,000-100,000 patients in the U.S. and about double that number globally. He indicated PLC is not close to profitability this year and that will be affected by when they get FDA approval and reimbursement approval. He indicated there are 980 hospitals in the U.S. doing some type of heart surgery and 30+ clinical sites. The last thing he discussed is that PLC is currently getting some reimbursement from insurance companies.